• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Spike 糖蛋白变体对 SARS-CoV-2 传播和免疫逃逸的结构评估。

Structural Evaluation of the Spike Glycoprotein Variants on SARS-CoV-2 Transmission and Immune Evasion.

机构信息

Department of Medical Microbiology & Parasitology, School of Medical Sciences, Universiti Sains Malaysia Health Campus, Kubang Kerian 16150, Malaysia.

Lydia Becker Institute of Immunology and Inflammation, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Oxford Road, Manchester M13 9PL, UK.

出版信息

Int J Mol Sci. 2021 Jul 10;22(14):7425. doi: 10.3390/ijms22147425.

DOI:10.3390/ijms22147425
PMID:34299045
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8306177/
Abstract

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents significant social, economic and political challenges worldwide. SARS-CoV-2 has caused over 3.5 million deaths since late 2019. Mutations in the spike (S) glycoprotein are of particular concern because it harbours the domain which recognises the angiotensin-converting enzyme 2 (ACE2) receptor and is the target for neutralising antibodies. Mutations in the S protein may induce alterations in the surface spike structures, changing the conformational B-cell epitopes and leading to a potential reduction in vaccine efficacy. Here, we summarise how the more important variants of SARS-CoV-2, which include cluster 5, lineages B.1.1.7 (Alpha variant), B.1.351 (Beta), P.1 (B.1.1.28/Gamma), B.1.427/B.1.429 (Epsilon), B.1.526 (Iota) and B.1.617.2 (Delta) confer mutations in their respective spike proteins which enhance viral fitness by improving binding affinity to the ACE2 receptor and lead to an increase in infectivity and transmission. We further discuss how these spike protein mutations provide resistance against immune responses, either acquired naturally or induced by vaccination. This information will be valuable in guiding the development of vaccines and other therapeutics for protection against the ongoing coronavirus disease 2019 (COVID-19) pandemic.

摘要

严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)的出现给全球带来了重大的社会、经济和政治挑战。自 2019 年底以来,SARS-CoV-2 已导致超过 350 万人死亡。刺突(S)糖蛋白的突变尤其令人关注,因为它包含识别血管紧张素转换酶 2(ACE2)受体的结构域,也是中和抗体的靶标。S 蛋白的突变可能会引起表面刺突结构的改变,改变构象 B 细胞表位,并导致疫苗效力的潜在降低。在这里,我们总结了 SARS-CoV-2 的一些更重要的变异株,包括第 5 簇、谱系 B.1.1.7(Alpha 变异株)、B.1.351(Beta)、P.1(B.1.1.28/Gamma)、B.1.427/B.1.429(Epsilon)、B.1.526(Iota)和 B.1.617.2(Delta),它们在各自的刺突蛋白中发生突变,通过提高与 ACE2 受体的结合亲和力,增强病毒适应性,并导致感染性和传染性的增加。我们进一步讨论了这些刺突蛋白突变如何提供对免疫反应的抵抗力,无论是自然获得的还是疫苗诱导的。这些信息对于指导针对持续的 2019 年冠状病毒病(COVID-19)大流行的疫苗和其他治疗方法的开发将是有价值的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d722/8306177/6ab99bcbfe14/ijms-22-07425-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d722/8306177/a1f04df39b7b/ijms-22-07425-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d722/8306177/9164d5922590/ijms-22-07425-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d722/8306177/7c296528523f/ijms-22-07425-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d722/8306177/f845ada10d1f/ijms-22-07425-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d722/8306177/3e246dc6584d/ijms-22-07425-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d722/8306177/4fc7255c66e0/ijms-22-07425-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d722/8306177/6ab99bcbfe14/ijms-22-07425-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d722/8306177/a1f04df39b7b/ijms-22-07425-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d722/8306177/9164d5922590/ijms-22-07425-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d722/8306177/7c296528523f/ijms-22-07425-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d722/8306177/f845ada10d1f/ijms-22-07425-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d722/8306177/3e246dc6584d/ijms-22-07425-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d722/8306177/4fc7255c66e0/ijms-22-07425-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d722/8306177/6ab99bcbfe14/ijms-22-07425-g007.jpg

相似文献

1
Structural Evaluation of the Spike Glycoprotein Variants on SARS-CoV-2 Transmission and Immune Evasion. Spike 糖蛋白变体对 SARS-CoV-2 传播和免疫逃逸的结构评估。
Int J Mol Sci. 2021 Jul 10;22(14):7425. doi: 10.3390/ijms22147425.
2
Mutations in the SARS-CoV-2 spike receptor binding domain and their delicate balance between ACE2 affinity and antibody evasion.SARS-CoV-2 刺突受体结合域的突变及其在与 ACE2 亲和力和抗体逃逸之间的微妙平衡。
Protein Cell. 2024 May 28;15(6):403-418. doi: 10.1093/procel/pwae007.
3
AlphaFold2 Modeling and Molecular Dynamics Simulations of the Conformational Ensembles for the SARS-CoV-2 Spike Omicron JN.1, KP.2 and KP.3 Variants: Mutational Profiling of Binding Energetics Reveals Epistatic Drivers of the ACE2 Affinity and Escape Hotspots of Antibody Resistance.AlphaFold2 对 SARS-CoV-2 刺突奥密克戎 JN.1、KP.2 和 KP.3 变体构象集合的建模和分子动力学模拟:结合能突变分析揭示 ACE2 亲和力的上位驱动因素和抗体耐药性逃逸热点。
Viruses. 2024 Sep 13;16(9):1458. doi: 10.3390/v16091458.
4
Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants.刺突蛋白结构特征、决定病毒进入宿主细胞的物种特异性血管紧张素转换酶 2 残基,以及奥密克戎 BA.1、BA.1.1、BA.2 和 BA.3 变异株的抗体中和逃逸。
J Virol. 2022 Sep 14;96(17):e0114022. doi: 10.1128/jvi.01140-22. Epub 2022 Aug 24.
5
BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.BA.2.12.1、BA.4 和 BA.5 逃避奥密克戎感染诱导的抗体。
Nature. 2022 Aug;608(7923):593-602. doi: 10.1038/s41586-022-04980-y. Epub 2022 Jun 17.
6
Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics.常见突变对 SARS-CoV-2 刺突 RBD 及其配体人 ACE2 受体结合亲和力和动力学的影响。
Elife. 2021 Aug 26;10:e70658. doi: 10.7554/eLife.70658.
7
Mutation-induced changes in the receptor-binding interface of the SARS-CoV-2 Delta variant B.1.617.2 and implications for immune evasion.突变诱导的 SARS-CoV-2 德尔塔变异株 B.1.617.2 受体结合界面变化及其对免疫逃逸的影响。
Biochem Biophys Res Commun. 2021 Oct 15;574:14-19. doi: 10.1016/j.bbrc.2021.08.036. Epub 2021 Aug 15.
8
Ensemble-Based Mutational Profiling and Network Analysis of the SARS-CoV-2 Spike Omicron XBB Lineages for Interactions with the ACE2 Receptor and Antibodies: Cooperation of Binding Hotspots in Mediating Epistatic Couplings Underlies Binding Mechanism and Immune Escape.基于集成的SARS-CoV-2刺突奥密克戎XBB谱系与ACE2受体及抗体相互作用的突变分析和网络分析:结合热点在介导上位性偶联中的协同作用是结合机制和免疫逃逸的基础
Int J Mol Sci. 2024 Apr 12;25(8):4281. doi: 10.3390/ijms25084281.
9
Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants.SARS-CoV-2 变体增强感染性和免疫逃避的结构基础。
Science. 2021 Aug 6;373(6555):642-648. doi: 10.1126/science.abi9745. Epub 2021 Jun 24.
10
SARS-CoV-2 Entry Related Viral and Host Genetic Variations: Implications on COVID-19 Severity, Immune Escape, and Infectivity.SARS-CoV-2 进入相关的病毒和宿主遗传变异:对 COVID-19 严重程度、免疫逃避和传染性的影响。
Int J Mol Sci. 2021 Mar 17;22(6):3060. doi: 10.3390/ijms22063060.

引用本文的文献

1
Newly Characterized Porcine Epidemic Diarrhea Virus GII Subtype Strain.新鉴定的猪流行性腹泻病毒GII亚型毒株。
Transbound Emerg Dis. 2023 May 9;2023:5544724. doi: 10.1155/2023/5544724. eCollection 2023.
2
Structural biology of Nipah virus G and F glycoproteins: Insights into therapeutic and vaccine development.尼帕病毒G和F糖蛋白的结构生物学:对治疗和疫苗开发的见解
Eur J Microbiol Immunol (Bp). 2025 Apr 22;15(2):83-93. doi: 10.1556/1886.2025.00017. Print 2025 Jun 30.
3
Prediction of hospitalization time probability for COVID-19 patients with statistical and machine learning methods using blood parameters.

本文引用的文献

1
ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7.ChAdOx1 nCoV-19(阿斯利康疫苗)可保护叙利亚仓鼠免受 SARS-CoV-2 B.1.351 和 B.1.1.7 的侵害。
Nat Commun. 2021 Oct 7;12(1):5868. doi: 10.1038/s41467-021-26178-y.
2
B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies.B.1.526 型 SARS-CoV-2 变异株在纽约市被疫苗诱导和治疗性单克隆抗体中和。
mBio. 2021 Aug 31;12(4):e0138621. doi: 10.1128/mBio.01386-21. Epub 2021 Jul 27.
3
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.
使用血液参数,通过统计和机器学习方法预测新冠病毒肺炎患者的住院时间概率
Ann Med Surg (Lond). 2024 Sep 4;86(12):7125-7134. doi: 10.1097/MS9.0000000000002477. eCollection 2024 Dec.
4
Handgrip strength as a prognostic factor for COVID-19 mortality among older adult patients admitted to the intensive care unit (ICU): a comparison Alpha (B.1.1.7) and Delta (B.1.617.2) variants.握力作为入住重症监护病房(ICU)老年患者 COVID-19 死亡率的预后因素:Alpha(B.1.1.7)和 Delta(B.1.617.2)变异株的比较。
Sci Rep. 2024 Aug 27;14(1):19927. doi: 10.1038/s41598-024-71034-w.
5
Analysis of SARS-CoV-2 genome evolutionary patterns.分析 SARS-CoV-2 基因组的进化模式。
Microbiol Spectr. 2024 Feb 6;12(2):e0265423. doi: 10.1128/spectrum.02654-23. Epub 2024 Jan 10.
6
Distinctive Combinations of RBD Mutations Contribute to Antibody Evasion in the Case of the SARS-CoV-2 Beta Variant.SARS-CoV-2 贝塔变异株中 RBD 突变的独特组合导致抗体逃逸。
J Microbiol Biotechnol. 2023 Dec 28;33(12):1587-1295. doi: 10.4014/jmb.2308.08020. Epub 2023 Nov 3.
7
Differences in the inflammatory response among hospitalized patients with distinct variants of SARS-CoV-2.不同 SARS-CoV-2 变异株住院患者的炎症反应差异。
Front Immunol. 2023 Oct 16;14:1267991. doi: 10.3389/fimmu.2023.1267991. eCollection 2023.
8
A Computational Workflow to Predict Biological Target Mutations: The Spike Glycoprotein Case Study.一种预测生物靶标突变的计算工作流程:以刺突糖蛋白为例。
Molecules. 2023 Oct 14;28(20):7082. doi: 10.3390/molecules28207082.
9
Monitoring and tracking the spread of SARS-CoV-2 in Asturias, Spain.监测和追踪西班牙阿斯图里亚斯地区新冠病毒(SARS-CoV-2)的传播情况。
Access Microbiol. 2023 Sep 27;5(9). doi: 10.1099/acmi.0.000573.v4. eCollection 2023.
10
Analysis of the N-glycosylation profiles of the spike proteins from the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2.分析 SARS-CoV-2 的 Alpha、Beta、Gamma 和 Delta 变体的刺突蛋白的 N-糖基化谱。
Anal Bioanal Chem. 2023 Aug;415(19):4779-4793. doi: 10.1007/s00216-023-04771-y. Epub 2023 Jun 24.
Covid-19 疫苗对 B.1.617.2(德尔塔)变异株的有效性。
N Engl J Med. 2021 Aug 12;385(7):585-594. doi: 10.1056/NEJMoa2108891. Epub 2021 Jul 21.
4
SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern.关注变异株 B.1.427/B.1.429 逃避 SARS-CoV-2 免疫。
Science. 2021 Aug 6;373(6555):648-654. doi: 10.1126/science.abi7994. Epub 2021 Jul 1.
5
Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity.SARS-CoV-2 天然突变对刺突结构、构象和抗原性的影响。
Science. 2021 Aug 6;373(6555). doi: 10.1126/science.abi6226. Epub 2021 Jun 24.
6
Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021.截至2021年6月,严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变异株的传播性增加及其在全球的传播情况。
Euro Surveill. 2021 Jun;26(24). doi: 10.2807/1560-7917.ES.2021.26.24.2100509.
7
BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants.BNT162b2 诱导的针对 B.1.617 和其他 SARS-CoV-2 变体的中和作用。
Nature. 2021 Aug;596(7871):273-275. doi: 10.1038/s41586-021-03693-y. Epub 2021 Jun 10.
8
Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies.两种强效 SARS-CoV-2 中和抗体对新兴 B.1.351 和 B.1.1.7 变体的适应结构基础。
Structure. 2021 Jul 1;29(7):655-663.e4. doi: 10.1016/j.str.2021.05.014. Epub 2021 Jun 9.
9
Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination.BNT162b2疫苗对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变异株B.1.617.2和B.1.351的中和抗体活性
Lancet. 2021 Jun 19;397(10292):2331-2333. doi: 10.1016/S0140-6736(21)01290-3. Epub 2021 Jun 3.
10
SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的B.1.1.7和B.1.351刺突变异体与人类血管紧张素转换酶2(ACE2)的结合亲和力增强。
Lancet Infect Dis. 2021 Aug;21(8):1070. doi: 10.1016/S1473-3099(21)00262-0. Epub 2021 May 19.